On Thursday, January 16, 2025, the Indian benchmark indices Sensex gained by 318.74 points, or 0.42%, to close at 77,042.82, while the Nifty 50 surged by 98.60 points, or 0.42%, ending at 23,311.80. Check out a few stocks that might be in focus during the trading session on Friday.
Reliance Industries reported a 7.4% increase in its net profit for the December quarter, driven by a strong performance in its retail segment and growth in telecom earnings. For Q3 of FY25, the company posted a consolidated net profit of ₹18,540 crore (₹13.70 per share), compared to ₹17,265 crore (₹12.76 per share) during the same quarter last year. This also marked an increase from ₹16,563 crore in the preceding July-September quarter.
Axis Bank, a private sector lender, reported a 4% increase in its standalone net profit, reaching ₹6,304 crore for the third quarter ending December 31, 2024. In comparison, the bank’s net profit for the same period in the previous year was ₹6,071 crore. The bank’s total income for the quarter rose to ₹36,926 crore, up from ₹33,516 crore in the corresponding quarter of the previous year, according to a regulatory filing.
Infosys, India’s second-largest IT services company, reported an 11.46% increase in its net profit for the third quarter, driven by stronger demand. This surge in profits led the company to revise its annual sales projection upwards for the third time this fiscal year. For Q3 FY25, the company’s net profit stood at ₹6,806 crore, up from ₹6,106 crore in the same quarter last year, according to a statement. Revenue grew by 7.6%, reaching ₹41,764 crore.
BPCL announced that it has secured a major loan agreement worth ₹31,802 crore with a consortium led by the State Bank of India. The funds will be used to finance the construction of a petrochemical complex and the expansion of its refinery capacity at Bina, Madhya Pradesh. The consortium includes several banks, such as Punjab National Bank, Union Bank of India, Canara Bank, Bank of India, and the Export-Import Bank of India.
Havells, a consumer electrical goods manufacturer, reported a 3% decline in its net profit, which stood at ₹278 crore for the third quarter ending December 31, 2024. This compares to ₹287 crore in the same quarter of the previous year. The company’s revenue from operations grew by 10.8%, reaching ₹4,889 crore, up from ₹4,414 crore in the corresponding period of the prior fiscal year.
AstraZeneca has been granted approval by the Central Drugs Standard Control Organisation (CDSCO) to import eculizumab concentrate, sold under the brand name Soliris. The approval, issued in Form CT-20, allows the company to sell and distribute the medication in India.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 17, 2025, 8:45 AM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
